Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-20 of 25
Keywords: L-Dopa
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (2009) 62 (2): 114–119.
Published Online: 12 June 2009
... bradykinesia, which we validated by assessing the therapeutic effects of L -dopa and STN-HFS in PD patients (fig. 1 ). The aim of this study was to examine whether the simple tapping task can be subdivided into a proximal and a distal component, and whether these are modulated differentially by therapeutic...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1994) 34 (Suppl. 3): 17–19.
Published Online: 27 February 2008
...Sadako Kuno L-Dopa pioneered the symptomatic therapy of Parkinson’s disease. While this treatment proved effective in the treatment of parkinsonian akinesia, rigidity and tremor, prolonged L-dopa treatment was often noted to result in dyskinesia, psychosis and ‘on-off phenomena. This increasing...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1996) 36 (Suppl. 1): 38–42.
Published Online: 21 February 2008
.... Parkinson’s disease Motor fluctuations L-Dopa On-off Dyskinesias ...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1990) 30 (2): 108–111.
Published Online: 14 February 2008
...A.M.O. Bakheit; L.M. Henderson; A.P. Moore; J.A. Simpson; M. Thomas The quality and duration of control in two groups of parkinsonian patients under treatment with an L-dopa-based drug alone or L-dopa-based drug which has been partially substituted with bromocriptine are being compared over a 5...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1990) 30 (Suppl. 1): 31–40.
Published Online: 12 February 2008
... to abnormalities in the DA neuronal system. IDPN-induced dyskinesia was enhanced by administration of L-dopa, which increases DA concentration, but was completely inhibited by ceruletide, which inhibits DA release. The dyskinesia was also inhibited by sulpiride, a central antagonist of D2 DA receptors...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1987) 27 (1): 35–38.
Published Online: 05 February 2008
...M.A. Bédard; J. Montplaisir; R. Godbout Five narcoleptic patients presenting periodic movements in sleep were investigated during treatment with L-dopa administered together with a decarboxylase inhibitor. One of these patients was also treated with gamma-hydroxybutyrate and zimelidine...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1988) 28 (5): 291–294.
Published Online: 05 February 2008
...Fumiko Ishizaki; Seiho Nishikawa In 21 parkinsonian patients, we investigated the contents of blood serotonin (5HT) and benzylamine oxidase (BzAO) before and during L-dopa therapy. Then, we studied the patients prospectively, and evaluated the relationship between 5HT and BzAO and the clinical...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1982) 21 (4): 227–234.
Published Online: 30 January 2008
...T.C.A.M. van Woerkom; J.M. Minderhoud; T. Gottschal; G. Nicolai Results of treatment with L-dopa and/or physostigmine of patients with severe head injuries were examined and discussed. This treatment given to patients still unconscious a long period after trauma resulted in clinical improvement...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1980) 19 (1): 43–48.
Published Online: 29 January 2008
...M. Streifler; E. Avrami; J.M. Rabey Sebum secretion was studied in 14 parkinsonian patients before and after 3 months of treatment with L -dopa. An abnormality of sebum secretion was shown to exist in parkinsonism. In 7 patients, successfully treated with L -dopa, sebum secretion diminished and its...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1981) 20 (2): 118–124.
Published Online: 29 January 2008
... of the patients were studied again after 2 weeks of treatment with L-dopa + decarboxylase inhibitor. HVA excretion increased 20-fold while c-AMP excretion decreased 9% (p less 0.05). The reduction in the c-AMP excretion was observed only in the subgroups with akinesia or rigidity as the main symptom (p less 0.025...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1978) 17 (5): 271–275.
Published Online: 29 January 2008
... the clinical conditions of these patients, especially concerning the psychic performances. Base night recordings show sleep disruption, with a large amount of wakefulness at the beginning of the registrations and during the night itself; sleep stages are strongly reduced, especially REM sleep. After L -dopa...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1976) 14 (3): 219–228.
Published Online: 25 January 2008
...S. Algeri; S. Ruggieri; F. Miranda; M. Casacchia; P.L. Morselli; A. Agnoli The plasma concentration of dopa was studied in 15 parkinsonian patients after a single administration of L-dopa. The study was undertaken in order to determine if correlation between plasma dopa concentration and clinical...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1976) 14 (3): 229–239.
Published Online: 25 January 2008
...G. Rosati; M. Maioli; I. Aiello; A. Farris; V. Agnetti Carbohydrate metabolism and insulin secretion were investigated in 26 patients with Parkinson’s disease before and during L-dopa treatment. Oral glucose tolerance tests were performed on 13 patients treated with L-dopa alone and on 7 patients...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1975) 13 (4): 339–349.
Published Online: 25 January 2008
...Per Dietrichson; Jan Presthus; Robert Holmsen Twelve parkinsonian patients with an unsatisfactory therapeutic result on L-Dopa alone due to nausea, vomiting and involuntary movements were treated with L-Dopa and decarboxylase inhibitor. The daily dose reached 800 mg L-Dopa and 200 mg decarboxylase...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1976) 14 (1): 68–76.
Published Online: 25 January 2008
...M. Streifler; M. Kesten; M. Loewenthal; T. Aldor; T. Gilat Twelve patients with long-standing Parkinson’s disease, treated successfully with a combination of L-dopa and an inhibitor of aromatic L-amino acid decarboxylase (Ro 4–4602), in the ratio 4:1, were screened for damage to various organ...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1977) 15 (1): 34–39.
Published Online: 25 January 2008
... greater impairment in dysarthria and pyramidal tract indexes of patients with thalamotomy. L -Dopa and carbidopa therapy failed to significantly improve speech in any group. 24 11 1975 7 01 1976 25 1 2008 © 1977 S. Karger AG, Basel 1977 Copyright / Drug Dosage / Disclaimer...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1976) 14 (5): 321–327.
Published Online: 25 January 2008
...H. Zumstein; J. Siegfried Since L-dopa in combination with a decarboxylase inhibitor is currently the most effective therapy available for treatment of Parkinson’s disease, the authors compare the actual causes of death in a large series of treated Parkinson patients with a normal population...
Journal Articles
Subject Area:
Neurology and Neuroscience
S.R. Bareggi, M. Porta, A. Selenati, B.M. Assael, G. Calderini, M. Collice, M. Rossanda, P.L. Morselli
Journal:
European Neurology
Eur Neurol (1975) 13 (6): 528–544.
Published Online: 25 January 2008
...±0.10). Monitoring of lumbar HVA and 5HIAA over time, before, during and after L-dopa treatment, revealed interesting correlations between modification of clinical picture and the levels of monoamines acid metabolites. The data indicate a profound alteration of brain monoamines in chronic syndromes...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1972) 8 (6): 339–351.
Published Online: 24 January 2008
...M.R. Caccia; G. Avanzini; S. Negri The following problems were considered: (1) nature of the asynchronous response in the glabellar reflex (GR); (2) changes in the GR parameters induced by L-dopa; (3) changes induced by the drug in the masseter muscle silent period (SP); (4) meaning...
Journal Articles
Subject Area:
Neurology and Neuroscience
Journal:
European Neurology
Eur Neurol (1972) 7 (4): 228–240.
Published Online: 23 January 2008
...U.K. Rinne; V. Sonninen; T. Siirtola Treatment of Parkinson’s disease with amantadine and L-dopa was studied in 82 patients. A double-blind cross-over trial with 38 patients showed a significant benefit with 200 mg of amantadine daily. During non-blind treatment with 300 mg of amantadine for 2–4...
1